{
  "metadata": {
    "case_id": 49,
    "model": "GPT-5.1",
    "timestamp": "2025-11-29T16:32:17.544500",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/49_NCT03388164.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/GPT-5.1/49_GPT-5.1.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.78,
          0.7
        ],
        [
          0.95,
          0.7
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 1,
          "score": 0.7,
          "status": "matched",
          "ref_item": {
            "label": "Escitalopram + RT2CK17",
            "type": "ACTIVE_COMPARATOR",
            "description": "10mg escitalopram + 5mg RT2CK17 will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the placebo comparator by a local compounding pharmacy in Tulsa, Oklahoma.",
            "interventionNames": [
              "Drug: Escitalopram + RT2CK17"
            ]
          },
          "pred_item": {
            "label": "Methylphenidate + Escitalopram",
            "type": "EXPERIMENTAL",
            "description": "Participants received a compound capsule containing methylphenidate 5 mg plus escitalopram 10 mg daily for 8 weeks, with an option at week 4 to increase escitalopram to 20 mg (still combined with methylphenidate 5 mg). Study Drug B (and D after dose increase) bottles were equipped with a MEMS tracking cap.",
            "interventionNames": [
              "Methylphenidate",
              "Escitalopram"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 0,
          "score": 0.95,
          "status": "matched",
          "ref_item": {
            "label": "Escitalopram + Placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "10mg escitalopram + 5mg placebo will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the active comparator by a local compounding pharmacy in Tulsa, Oklahoma.",
            "interventionNames": [
              "Drug: Escitalopram + Placebo"
            ]
          },
          "pred_item": {
            "label": "Placebo + Escitalopram",
            "type": "PLACEBO_COMPARATOR",
            "description": "Participants received a compound capsule containing placebo 5 mg plus escitalopram 10 mg daily for 8 weeks, with an option at week 4 to increase escitalopram to 20 mg (still combined with placebo). Study Drug A (and C after dose increase) bottles were equipped with a MEMS tracking cap.",
            "interventionNames": [
              "Escitalopram",
              "Placebo capsule"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.72,
          0.42,
          0.5
        ],
        [
          0.78,
          0.55,
          0.9
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.72,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Escitalopram + RT2CK17",
            "description": "Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.",
            "armGroupLabels": [
              "Escitalopram + RT2CK17"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Escitalopram",
            "description": "First-line antidepressant administered orally in compounded capsules at an initial dose of 10 mg once daily for 8 weeks, with an option at week 4 to increase the escitalopram dose to 20 mg once daily based on lack of clinical improvement, in combination with either placebo or 5 mg methylphenidate.",
            "armGroupLabels": [
              "Placebo + Escitalopram",
              "Methylphenidate + Escitalopram"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 2,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Escitalopram + Placebo",
            "description": "Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.",
            "armGroupLabels": [
              "Escitalopram + Placebo"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Placebo capsule",
            "description": "Inert placebo 5 mg capsule compounded together with escitalopram (10 mg or 20 mg) and administered orally once daily for 8 weeks, matching the appearance of methylphenidate-containing capsules.",
            "armGroupLabels": [
              "Placebo + Escitalopram"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.9
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "Rate of Adherence",
            "description": "To determine whether RT2CK17 + escitalopram results in higher rates of medication adherence relative to placebo + escitalopram as measured by percentage pill count",
            "timeFrame": "8 weeks"
          },
          "pred_item": {
            "measure": "% adherence based on pill count",
            "description": "Percent pill count defined as 100 * [number of prescribed pills – number of pills remaining] / [number of days between dispensing date and return date]; analyzed on logit scale with linear mixed-effects models and contrast of MPH vs placebo at Week 8.",
            "timeFrame": "Weeks 2, 4, and 8 of the 8-week treatment period, with primary contrast at Week 8"
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.92
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.92,
          "status": "matched",
          "ref_item": {
            "measure": "Adherence Consistency",
            "description": "To determine whether RT2CK17 + escitalopram results in greater consistency of adherence relative to placebo + escitalopram as measured by percentage of doses taken on schedule within 25% of the expected time interval, defined as +/- 6 hours from the participant's breakfast time",
            "timeFrame": "8 weeks"
          },
          "pred_item": {
            "measure": "% adherence based on Medication Electronic Monitoring System (MEMS)",
            "description": "Percent of doses taken on schedule within 25% of the expected time interval (±6 hours from when the participant usually took the medication), calculated using MEMS caps and estimated dosing-time line; analyzed on logit scale with linear mixed-effects models and contrast of MPH vs placebo at Week 8.",
            "timeFrame": "Weeks 2, 4, and 8 of the 8-week treatment period, with primary contrast at Week 8"
          }
        }
      ]
    }
  ]
}